NAIR, PRADIP,MELARKODE, RAMAKRISHNAN,MANIAN, BALA S.,BARVE, ABHIJIT,BUGHANI, USHA,MONTERO CASIMIRO, JOSE ENRIQUE
申请号：
TW103125275
公开号：
TW201511772A
申请日:
2014.07.24
申请国别(地区):
TW
年份:
2015
代理人:
摘要：
The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.本揭露內容用於有關治療以及預防由T輔助型17（Th17）及/或T輔助型1（Th1）T淋巴球（T細胞）所媒介的疾病症狀的方法。特別是，本揭露內容有關抗CD6抗體的使用，用於治療由自身反應性Th17以及Th1 T淋巴球所媒介的疾病症狀。本揭露內容的方法在藉由抑制細胞激素IL-23R的產生，藉此減少由Th17細胞所媒介的發炎反應，而用於調節免疫反應的方法中更具有利用性。
